会议召开方式：上证路演中心网络互动 证券代码：605507 证券简称：国邦医药 公告编号：2023-031 国邦医药集团股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 11 月 1 日（星期三）下午 13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 投资者可于 2023 年 10 月 25 日（星期三）至 10 月 31 日（星期二）16:00 前 登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 （ https://roadshow.sseinfo.com/questionCollection.do ） 或 通 过 公 司 邮 箱 info@gbgcn.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 国邦医药集团股份有限公司（以 ...

证券代码：605507 证券简称：国邦医药 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 第三季度财务报表是否经审计 2023 年第三季度报告 2023 年第三季度报告 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 □是 √否 (一)主要会计数据和财务指标 1 / 12 | --- | --- | --- | --- | --- | |---------------------------------|------------------|----------------------|------------------|-----------------------------------------| | | | | | | | （元/股） | | | | | | 稀释每股收益 （元 / 股） | 0.24 | | -40.00 0.88 | -31.78 | | 加权平均净资产收益 率（ %） | 1.82 | 减少 ...

2023 年 9 月 4 日，公司提前归还 2 亿元至公司募集资金专用账户并已通知 保荐机构及保荐代表人，剩余尚未归还的募集资金金额为 2 亿元，使用期限未超 过 12 个月。公司将在规定期限内将剩余暂时补充流动资金的募集资金归还至募 集资金专用账户，并及时履行信息披露义务。 关于提前归还部分暂时补充流动资金的募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 国邦医药集团股份有限公司（以下简称"公司"）于 2023 年 4 月 14 日召开 了公司第二届董事会第二次会议、第二届监事会第二次会议，审议通过了《关于 归还募集资金并继续使用部分闲置募集资金暂时补充流动资金的议案》，同意公 司使用不超过人民币 4 亿元闲置募集资金暂时补充流动资金，使用期限自本次董 事会批准之日起 12 个月内有效。保荐机构和公司独立董事均发表了同意意见。 具体内容详见公司披露于上海证券交易所网站（www.sse.com.cn）的《国邦医药 关于归还募集资金并继续使用部分闲置募集资金暂时补充流动资金的公告》（公 告编号：2023-011） ...

Financial Performance - The net profit attributable to shareholders decreased by 27.79% year-on-year, primarily due to market competition and a decline in the prices of the company's main products [26]. - Basic earnings per share for the reporting period (January to June) was CNY 0.64, down from CNY 0.89 in the same period last year, representing a decrease of 28.09% [31]. - Diluted earnings per share for the reporting period was also CNY 0.64, reflecting the same percentage decrease of 28.09% year-on-year [31]. - The weighted average return on net assets was 4.91%, a decrease of 2.62 percentage points compared to 7.53% in the same period last year [31]. - The company's operating revenue for the first half of 2023 was ¥2,809,720,242.62, representing a 3.93% increase compared to the same period last year [37]. - The net profit attributable to shareholders decreased by 27.79% to ¥357,470,775.26 from ¥495,038,347.85 in the previous year [37]. - The total comprehensive income for the period was approximately CNY 357.47 million, with a decrease of CNY 614,412.21 compared to the previous period [156]. - The total equity attributable to shareholders as of June 30, 2023, was ¥5,144,849,912.33, down from ¥5,466,830,215.78 in the previous year, reflecting a decrease of approximately 5.86% [190]. Cash Flow and Operating Activities - The net cash flow from operating activities decreased by 84.76% year-on-year, mainly due to significant prepayments made to ensure the supply of key raw materials [26]. - The net cash flow from operating activities dropped significantly by 84.76% to ¥31,980,639.50, down from ¥209,914,490.68 [37]. - Operating cash inflow for the first half of 2023 reached CNY 2,102,569,752.56, an increase from CNY 1,835,702,906.11 in the same period of 2022, representing a growth of approximately 14.6% [195]. - Cash received from sales of goods and services amounted to CNY 1,877,941,140.48, compared to CNY 1,680,539,839.59 in the previous year, indicating an increase of about 11.7% [195]. - Total cash paid for goods and services was CNY 1,531,991,285.60, up from CNY 1,112,131,460.02 in the first half of 2022, reflecting a significant rise of approximately 37.7% [195]. - The company received tax refunds and other cash related to operating activities totaling CNY 168,692,660.52, compared to CNY 119,975,881.94 in the previous year, marking an increase of about 40.5% [195]. Assets and Liabilities - The total assets increased by 6.72% to ¥9,650,952,129.43 compared to the end of the previous year [37]. - The total assets as of June 30, 2023, amounted to ¥5,866,103,269.03, an increase from ¥5,737,803,529.09 at the end of 2022 [189]. - The company's non-current assets totaled approximately CNY 4.51 billion, up from CNY 3.91 billion, indicating an increase of around 15.3% [186]. - Current liabilities amounted to approximately CNY 2.07 billion, compared to CNY 1.86 billion in the previous period, representing an increase of about 11.0% [186]. - The company's total liabilities increased to approximately CNY 2.07 billion, up from CNY 1.86 billion, indicating a rise of about 11.0% [186]. Shareholder Information - The company reported a total of 558,823,500 shares outstanding, with 46.01% being subject to lock-up restrictions after the IPO [108]. - The top ten shareholders hold a significant portion of the company's equity, with the largest shareholder being New Chang Ande Trading Co., Ltd. [175]. - The top shareholder, Xinchang Ander Trading Co., Ltd., holds 128,951,976 shares, representing 23.08% of the total shares [197]. - The second-largest shareholder, Xinchang Qingyu Investment Development Co., Ltd., holds 73,296,367 shares, accounting for 13.12% of the total shares [197]. - The company has a lock-up period for shares held by its partners, which may be extended if the stock price falls below the IPO price for a specified period [72]. Governance and Compliance - The company has committed to avoiding any direct or indirect competition with its controlling shareholders and related parties, ensuring the protection of minority shareholders' interests [73]. - The company has a strict policy to avoid related party transactions unless unavoidable, ensuring that any such transactions are conducted on an equal and voluntary basis at fair market prices [74]. - The company has established a risk management mechanism to monitor exchange rate fluctuations and employs forward foreign exchange contracts to mitigate risks associated with currency volatility [81]. - The company has committed to maintaining transparency and compliance with shareholder interests and regulatory requirements [99]. - There are no significant related party transactions or financial dealings reported during the period [103]. Environmental and Social Responsibility - The company has implemented advanced green processes and increased environmental investments to promote sustainable development [60]. - The company has established eight sets of RTO (Regenerative Thermal Oxidizer) facilities for comprehensive treatment of high-concentration organic waste gas, effectively utilizing the energy generated during combustion to reduce energy consumption and greenhouse gas emissions [90]. - The company has implemented measures to control noise pollution, ensuring that factory boundary noise levels meet the Class 3 standard of the Industrial Enterprise Factory Boundary Environmental Noise Emission Standard (GB12348-2008) [87]. - The company has implemented a wastewater treatment system that meets the Class A standard of the Urban Wastewater Treatment Plant Pollutant Discharge Standard (GB18918-2002) after secondary treatment [87]. Research and Development - Research and development expenses for the first half of 2023 were ¥97,438,359.97, up from ¥86,607,056.35 in the same period of 2022, indicating an increase of about 12.66% [190]. Miscellaneous - The company has not reported any major contracts or significant events during the reporting period [106]. - The company has not undergone any bankruptcy reorganization during the reporting period [102]. - The company has not experienced any major changes in its share capital structure during the reporting period [127]. - The company has not disclosed any new product or technology developments in the current report [125].

证券代码：605507 证券简称：国邦医药 公告编号：2023-024 国邦医药集团股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 7 月 28 日（星期五）至 8 月 3 日（星期四）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 info@gbgcn.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 （一）会议召开时间：2023 年 8 月 4 日（星期五）上午 10:00-11:00 国邦医药集团股份有限公司（以下简称"公司"）将于 2023 年 7 月 29 日发 布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半 年度经营成果、财务状况，公司计划于 2023 年 8 月 4 日（星期五）上 ...

Financial Performance - Operating revenue for Q1 2023 was CNY 1,410,162,706.26, up from CNY 1,176,098,332.11 in Q1 2022, reflecting a significant increase[22] - The company's operating revenue for Q1 2023 was CNY 1,410,162,706.26, representing a year-on-year increase of 19.90%[37] - The company reported a net profit of CNY 2,603,706.71 after accounting for various income and tax impacts[15] - The net profit attributable to shareholders for Q1 2023 was CNY 194,629,337.80, a decrease of 2.88% compared to the same period last year[37] - The company reported a decrease in total profit for Q1 2023, amounting to CNY 228,633,029.61, down from CNY 235,103,308.71 in the same period last year[46] - The net profit attributable to the parent company's shareholders was approximately $194.63 million, a decrease from $200.39 million in the previous period, representing a decline of about 2.4%[60] - The total comprehensive income amounted to approximately $194.97 million, down from $200.31 million, indicating a decrease of around 2.9%[60] Cash Flow - Cash flow from operating activities surged by 207% due to a significant increase in sales receipts compared to the same period last year[16] - The net cash flow from operating activities for Q1 2023 was CNY 210,380,795.68, showing a significant increase of 207.00% year-on-year[37] - Cash inflow from operating activities for Q1 2023 was approximately $1.06 billion, an increase of 38.5% compared to $762.99 million in Q1 2022[48] - Net cash flow from operating activities reached $210.38 million, significantly up from $68.53 million in the same period last year, marking a growth of 206.5%[48] - The net cash flow from investing activities for Q1 2023 was CNY 60,442,955.33, a turnaround from a negative cash flow of CNY 25,669,620.90 in the previous year[37] - The net cash flow from financing activities for Q1 2023 was CNY 87,791,452.32, compared to CNY 28,188,852.11 in the same period last year[37] Assets and Liabilities - Total assets increased by 8.13% to CNY 9,778,471,788.41 compared to CNY 9,043,184,958.17 in the previous period[4] - Total liabilities increased to CNY 2,428,895,365.25 from CNY 1,888,579,890.48, reflecting higher financial obligations[11] - Deferred income decreased to CNY 13,732,704.21 from CNY 14,266,913.85, showing a reduction in liabilities[11] - Non-current assets totaled CNY 4,106,680,270.21, an increase from CNY 3,913,865,466.88[21] - Short-term borrowings rose to CNY 748,600,555.56 from CNY 655,569,791.66, indicating increased leverage[21] Shareholder Information - The company reported a total of 28,499 common shareholders at the end of the reporting period[54] - The largest shareholder, Xinchang Ande Trading Co., Ltd., holds 23.08% of the shares, totaling 128,951,976 shares[54] Earnings and Expenses - The basic earnings per share for Q1 2023 was CNY 0.35, reflecting a decrease of 2.78% compared to the previous year[37] - The company's research and development expenses for Q1 2023 amounted to CNY 46,857,324.22, an increase from CNY 31,655,326.74 in the previous year[46] - Basic and diluted earnings per share were both reported at $0.35, a slight decrease from $0.36 in the previous period[60] Cash and Inventory - The total cash and cash equivalents at the end of the period reached CNY 1,934,456,200.04, up from CNY 643,928,226.66 at the end of the previous year[37] - Total current assets as of March 31, 2023, were approximately $5.67 billion, an increase from $5.13 billion at the end of 2022, showing a growth of 10.6%[57] - Cash and cash equivalents stood at $2.56 billion, compared to $1.97 billion at the end of 2022, reflecting a growth of 29.6%[57] - Inventory levels increased to $1.46 billion from $1.41 billion, marking a rise of 3.5%[57] Cash Flow from Sales - Total cash received from the sale of goods and services was approximately $963.37 million, compared to $694.82 million in Q1 2022, reflecting a year-over-year increase of 38.7%[48] - Cash paid for purchasing goods and services amounted to $595.59 million, up from $462.93 million in Q1 2022, representing a rise of 28.6%[48] - Cash received from investment recoveries was $559.63 million, down from $1.15 billion in Q1 2022, indicating a decrease of 51.3%[48]

Financial Performance - The company's operating revenue for 2022 was approximately CNY 5.72 billion, representing a year-on-year increase of 26.98% compared to CNY 4.51 billion in 2021[21]. - The net profit attributable to shareholders of the listed company reached approximately CNY 920.90 million, a growth of 30.43% from CNY 706.03 million in the previous year[21]. - The net cash flow from operating activities was approximately CNY 1.02 billion, a significant recovery from a negative cash flow of CNY 176.18 million in 2021[21]. - The total assets of the company at the end of 2022 were approximately CNY 9.04 billion, reflecting a year-on-year increase of 20.37% from CNY 7.51 billion in 2021[21]. - The net assets attributable to shareholders of the listed company were approximately CNY 7.16 billion, an increase of 12.75% compared to CNY 6.35 billion at the end of 2021[21]. - The company's basic earnings per share increased by 19.57% to CNY 1.65 in 2022 compared to CNY 1.38 in 2021[22]. - Net profit attributable to shareholders grew by 30.43%, driven by increased revenue and enhanced market competitiveness[23]. - Operating cash flow decreased due to reduced cash payments for procurement compared to the previous period[23]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of CNY 6 per 10 shares, totaling approximately CNY 335.29 million, subject to approval at the annual general meeting[5]. - The company’s profit distribution policy emphasizes a minimum cash dividend of 10% of the distributable profit for the year[156]. - The company declared a cash dividend of CNY 335,294,100, which accounts for 36.41% of the net profit attributable to ordinary shareholders in the consolidated financial statements[160]. Research and Development - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[21]. - In 2022, the company achieved a 27.22% year-on-year increase in R&D expenses, totaling CNY 198 million, with 68 controlled research projects and 78 patent applications filed[35]. - The company has a total of 496 R&D personnel, with 46.77% holding a bachelor's degree or higher[84]. - The company has maintained a strategy of combining independent R&D innovation with collaborative innovation to enhance product competitiveness[84]. - The company’s R&D investment for 2022 was CNY 197.54 million, an increase of 27.22% year-on-year, accounting for 3.45% of total revenue[84]. Market Expansion and Product Development - The company is actively expanding its global sales network, serving over 3,000 clients across 115 countries and regions[40]. - The company aims to achieve global leadership in 30 scaled products and regular production of 80 products, with a production capacity for 120 products[48]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 200 million RMB allocated for potential deals[136]. - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing product efficiency[136]. Environmental and Social Responsibility - The company invested CNY 192.74 million in environmental protection during the reporting period[166]. - The company has constructed 8 sets of RTO waste gas comprehensive treatment facilities to effectively collect and treat high-concentration organic waste gas, reducing energy consumption and greenhouse gas emissions[177]. - The company has implemented a strict management system for hazardous waste, ensuring proper classification, storage, and disposal in compliance with relevant regulations[172]. - The company has achieved 100% operational efficiency of waste gas absorption and treatment devices during production periods[171]. - The company donated 700,000 yuan to China Pharmaceutical University and 50,000 yuan to Shaoxing Charity Foundation during the reporting period[184]. Governance and Compliance - The company maintains a governance structure that ensures independent operation and compliance with legal regulations, protecting shareholder rights[124]. - The company has not faced any penalties from securities regulatory agencies in the past three years[141]. - The company has established an investor relations management system to ensure timely and accurate communication with investors[126]. - The independent directors participated in all board meetings, with no objections raised against company matters[145]. Strategic Planning and Future Outlook - The company is positioned to benefit from favorable government policies and increasing health awareness among the population, driving demand for pharmaceuticals[105]. - The company plans to enhance its marketing management system based on the "business unit" model, focusing on global market expansion[116]. - The company aims to improve operational efficiency by 15% through new manufacturing technologies[136]. - The company plans to complete 41 marketing projects in 2023, focusing on product positioning and market share goals[117].

证券代码：605507 证券简称：国邦医药 公告编号：2023-004 国邦医药集团股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 4 月 18 日（星期二）上午 10:00-11:00 投资者可于 2023 年 4 月 11 日（星期二）至 4 月 17 日（星期一）16:00 前登录上证路演中心网站首页点击 "提问预征集"栏目或通过公司邮箱 info@gbgcn.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 国邦医药集团股份有限公司（以下简称"公司"）拟于 2023 年 4 月 15 日发布 公司 2022 年年度报告和 2023 年第一季度报告，为便于广大投资者更全面深入地 了解公司 2022 年度和 2023 年第一季度的经营成果、财务状况，公司计划于 2023 年 4 月 18 日（星期二）上午 10:00-11:00 举行 2022 年度暨 2023 年第一季度业绩 说 ...

2022 年第三季度报告 单位：元 币种：人民币 1 / 12 证券代码：605507 证券简称：国邦医药 国邦医药集团股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |------------------------------------------------|------------------|--------------------------------------|------------------|------------------------- ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[19] - The net profit attributable to shareholders for the same period was RMB 100 million, up 20% compared to the previous year[19] - The gross margin improved to 45%, an increase of 5 percentage points from the previous year[19] - Revenue for the reporting period reached ¥2,703,468,710.18, representing a year-on-year increase of 20.56%[21] - Net profit attributable to shareholders was ¥495,038,347.85, reflecting a growth of 31.07% compared to the previous year[21] - The net profit after deducting non-recurring gains and losses was ¥489,031,219.87, an increase of 30.50% year-on-year[21] - Basic earnings per share for the first half of the year was ¥0.89, up 11.25% from ¥0.80 in the same period last year[22] - The company's operating revenue for the period reached ¥2,703,468,710.18, representing a 20.56% increase compared to ¥2,242,396,166.27 in the same period last year[65] - Net profit for the first half of 2022 was ¥494,995,032.30, representing a 31.0% increase from ¥378,032,059.91 in the previous year[174] User Growth and Market Expansion - User data showed a growth in active users by 30%, reaching a total of 1 million active users by the end of June 2022[19] - The company plans to launch two new products in Q3 2022, aiming to capture a larger market share in the pharmaceutical sector[19] - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[19] - The increase in revenue was primarily driven by the launch of new products and a recovery in sales within the pharmaceutical raw materials sector due to the impact of the COVID-19 pandemic[23] Research and Development - Research and development expenses increased by 25% to RMB 50 million, reflecting the company's commitment to innovation[19] - R&D investment increased by 26.55% year-on-year, with a total of 90 authorized patents, including 81 invention patents[53] - The company has developed over 30 pharmaceutical-related processes and maintains partnerships with top research institutions[51] - The company established a comprehensive R&D base in Zhejiang covering 20,000 square meters to enhance product development and process validation capabilities[65] - The company initiated the construction of a new R&D base in Shandong, designed to accommodate 800 scientific personnel[65] Financial Position and Assets - Total assets increased to ¥8,463,486,297.59, a rise of 12.65% compared to the end of the previous year[21] - The company's net assets attributable to shareholders grew by 6.04% to ¥6,729,390,631.89[21] - Current assets totaled ¥5,152,118,005.74, up from ¥4,567,298,104.73, indicating an increase of about 12.79%[162] - Cash and cash equivalents rose to ¥1,630,492,057.54 from ¥893,006,462.03, reflecting an increase of approximately 82.61%[162] - Total liabilities rose to ¥1,734,508,260.47 from ¥1,167,378,598.11, which is an increase of approximately 48.58%[164] Environmental and Quality Control - The company emphasizes strict quality control measures for its main products, raw materials, and key pharmaceutical intermediates, ensuring all production processes undergo rigorous quality evaluations[78] - The company maintains a comprehensive environmental management system, ensuring compliance with pollution discharge standards across various pollutants, with no exceedances reported[88] - The company has constructed 8 sets of RTO waste gas comprehensive treatment facilities, capable of handling a total air volume of 331,000 m³/h[91] - The company has installed 24 sets of online monitoring devices for environmental quality, which have been accepted and connected to the network[91] - The company has made significant investments in environmental protection technologies and equipment to enhance sustainable development[91] Shareholder Commitments and Governance - The controlling shareholder and actual controllers committed to not transferring or entrusting the management of shares for 36 months from the IPO date, with a lock-up period extending if stock prices fall below the IPO price[107] - The company has a share lock-up commitment for directors and senior executives for 12 months post-IPO, with a similar extension clause based on stock performance[109] - The company has committed to resolving industry competition and related transactions on a long-term basis, ensuring compliance with regulations[107] - The company has established a commitment to resolve land and property rights issues on a long-term basis, ensuring stability in operations[109] - The company has committed to avoiding any competition with its controlling shareholders and related parties to protect the interests of minority shareholders[125]